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Purpose: We compared outcome and durability of carotid stent-assisted angioplasty (CAS) with open surgical repair (ie,
repeat carotid endarterectomy [CEA]) to treat recurrent carotid stenosis (RCS).
Methods: A retrospective review of anatomic and neurologic outcomes was carried out after 27 repeat CEA procedures
(1993-2002) and 52 CAS procedures (1997-2002) performed to treat high-grade internal carotid artery (ICA) RCS after
CEA. The incidence of intervention because of symptomatic RCS was similar (repeat CEA, 63%; CAS, 60%), but the
interval from primary CEA to repeat intervention was greater (P < .05) in the repeat CEA group (83  15 months)
compared with the CAS group (50 8 months). In the CAS group, 17 of 52 arteries (33%) were judged not to be surgical
candidates because of surgically inaccessible high lesions (n  8), medical comorbid conditions (n  4), neck irradiation
(n  3), or previous surgery with cranial nerve deficit or stroke (n  2). Three patients who underwent repeat CEA had
lesions not appropriate for treatment with CAS.
Results: Overall 30-day morbidity was similar after CAS (12%; death due to ipsilateral intracranial hemorrhage, 1;
nondisabling stroke, 1; reversible neurologic deficits or transient ischemic attack, 2; access site complication, 2) and repeat
CEA (11%; no death; nondisabling stroke, 1; reversible cranial nerve injury, 1; cervical hematoma, 1). Combined stroke
and death rate was 3.7% for repeat CEA and 5.7% for CAS (P > .1). All duplex ultrasound scans obtained within 3 months
after CEA and CAS demonstrated patent ICA and velocity spectra of less than 50% stenosis. During follow-up, no repeat
CEA (mean, 39 months) or CAS (mean, 26 months) repair demonstrated ICA occlusion, but two patients (8%) who
underwent repeat CEA and 4 patients (8%) who underwent CAS required balloon or stent angioplasty because of 80%
RCS. At last follow-up, no patient had ipsilateral stroke and all ICA remain patent. At duplex scanning, stenosis-free
(<50% diameter reduction) ICA patency at 36 months was 75% after repeat CEA and 57% after CAS (P  .26, log-rank
test).
Conclusions: Carotid angioplasty for treatment of high-grade stenotic ICA after CEA resulted in similar anatomic and
neurologic outcomes compared with open surgical repair. Most lesions are amenable to endovascular therapy, and CAS
enabled treatment in patients judged not to be suitable surgical candidates. Duplex scanning surveillance after repeat CEA
or CAS is recommended, because stenosis can recur after either secondary procedure. (J Vasc Surg 2003;38:432-8.)
Management of recurrent carotid stenosis (RCS) after
surgical endarterectomy (CEA) remains controversial.
There is no consensus regarding criteria as to threshold
stenosis severity at which to intervene in asymptomatic
lesions, and the dilemma of surgical repair with patch
angioplasty versus carotid resection has been further com-
plicated by reports of comparable results with endovascular
management.1-7 Providing consul to patients with asymp-
tomatic RCS is cloaked in clinical uncertainty, in part
because of the relatively benign natural history of these
lesions and the morbidity associated with repeat CEA. RCS
is associated with lower risk for embolic complications, that
is, incidence of neurologic symptoms, than is primary ath-
erosclerotic carotid bifurcation stenosis, and when followed
by serial duplex scanning, regression of myointimal lesions
has been documented in more than 10% of patients.3,8
Because surgical intervention for RCS is perceived to be
associated with higher risk for perioperative stroke and
cranial nerve deficit, compared with primary CEA, it is not
surprising that stent-assisted angioplasty (CAS) has been
promoted as a less invasive, alternative treatment, especially
in patients with radiation-scarred necks or high internal
carotid artery (ICA) recurrent stenosis.9 Thus, when
weighing the decision as to whether to intervene in RCS,
the vascular surgeon must carefully consider the risks versus
potential clinical benefits of open versus endovascular repair
in each patient.
After CEA, RCS develops as a continuum, with early
recurrent stenosis the result of technically inadequate repair
or myointimal hyperplasia, whereas later lesions have a
more typical appearance of atherosclerosis. RCS that devel-
ops during the first year after CEA may involve an aggres-
sive proliferative process, but the lesion is smooth, and
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progression to ICA occlusion is more likely than thrombo-
embolism. Carotid angioplasty has been used principally for
treatment of myointimal recurrent stenosis that has devel-
oped within 3 years after CEA, and treatment of these
lesions is associated with high technical success, as well as
periprocedural complication rates comparable to those
with primary and repeat CEA.4,5,7,10,11 On the basis of
these favorable clinical reports, our vascular surgery divi-
sion, working in conjunction with an interventional neuro-
radiologist (A.E.), selected patients with RCS for CAS
versus repeat CEA, based on anatomic and patient factors,
or for inclusion in a multicenter clinical trial on the safety
and efficacy of CAS. This report details a comparative
analysis of outcome after operative or endovascular man-
agement of RCS, with the goals of providing clinical guide-
lines for intervention and determining whether CAS is
applicable in most RCS lesions encountered in a referral
vascular surgery practice.
METHODS
Records for patients who underwent treatment of RCS
were retrieved from a vascular registry that detailed symp-
toms at presentation, atherosclerotic risk factors, proce-
dural details of carotid stenosis repair, and duplex ultra-
sound scanning results. Inpatient and outpatient clinic
charts were then carefully reviewed for both intraproce-
dural and postprocedural complications and 30-day neuro-
logic morbidity and mortality. After discharge, patient fol-
low-up was accomplished by review of outpatient and
vascular laboratory records, with patient interview at clinic
visit or via telephone when indicated. Survival data were
supplemented with the Social Security Administration data
base system if patient follow-up was not complete.
In all patients who underwent CAS, cerebral angio-
grams were obtained before stenting, and these were re-
viewed for degree of stenosis (percent diameter reduction),
severity of contralateral disease, and presence of intracranial
cerebral artery occlusive disease. After intervention with
CAS or repeat CEA, all patients were followed up with
duplex ultrasound scanning of the extracranial carotid ar-
teries, as well as clinical evaluation, for development of
neurologic symptoms, including stroke, transient ischemic
attack (TIA), and amaurosis fugax. Patient demographic
data, including age, gender, atherosclerotic risk factors, and
medical comorbid conditions, and procedure outcome,
including patency, intervention to treat recurrent stenosis,
occlusion, or neurologic event, and survival, were com-
pared between the two treatment groups. Mean follow-up
for patients with repeat CEA was 38 months (range, 3-112
months), and for patients with CAS was 22 months (range,
3-60 months).
Patients. Over 10 years (1993-2002), 27 patients (19
men, 8 women) with symptomatic RCS (17 of 27; 63%) or
asymptomatic RCS (11 of 27; 41%) underwent repeat
CEA. During a concurrent 6 years (1997-2002), 50 pa-
tients (35 men, 15 women) with symptomatic RCS (31 of
52; 60%) or asymptomatic RCS (21 of 52; 40%) underwent
CAS. In only 3 of 77 patients (4%) was the original CEA
procedure performed by vascular surgery faculty; the re-
maining patients were referred for evaluation and manage-
ment of RCS. In general, intervention for symptomatic
RCS was recommended for all lesions with greater than
50% diameter reduction. For patients with asymptomatic
RCS, high-grade stenosis (80%) at duplex scanning (end-
diastolic velocity 145 cm/s at site of stenosis) and an-
giography was the clinical threshold for intervention. Five
of 27 patients (18%) with repeat CEA and 14 of 50 patients
(28%) with CAS had occlusion of the ICA contralateral to
RCS.
The method of vessel closure (primary closure, patch
angioplasty, unknown) at the original CEA was similar in
the repeat CEA (63%; 37%, 0%) and CAS (57%, 37%, 6%)
treatment groups, but the interval from CEA to repeat
intervention was longer (P .05) in the repeat CEA group
(83  15 months) compared with the CAS group (50  8
months).
Seventeen of 52 patients (33%) who underwent CAS,
all with symptomatic RCS, were judged by consultant
vascular surgeons not to be surgical candidates, because of
surgically inaccessible high lesions (n 8), comorbidity (n
 4), neck irradiation (n  3), or recent CEA with cranial
nerve deficit or scarred neck (n 1) or perioperative stroke
(n  1). Three patients who underwent repeat CEA had
lesions judged not appropriate for CAS, because of lumen
thrombus in RCS and perceived high risk for embolization
(n 2) or inability to safely stent the RCS because of vessel
tortuosity (n  1).
Procedures to treat RCS. All CAS procedures were
performed in the angiographic suite with biplane imaging,
under the direction of an interventional neuroradiologist
(A.E.) experienced in cerebrovascular interventions. Before
CAS, patients were given platelet inhibitors (aspirin, 325
mg/d; clopidogrel, 300 mg bolus, then 75 mg/d). Angio-
plasty procedures were performed with local anesthetic at
the femoral or brachial (1 patient) puncture site, intrave-
nous sedation, and monitored anesthetic techniques. Be-
fore selective catheterization, patients underwent systemic
heparinization (activated clotting time 250 s). Self-
expanding stents were preferentially used (Table I), as was
predilation of the RCS lesion with a 3 or 4 mm balloon.
Balloon-expandable stents were used in select patients only
Table I. Type and size of stents used in 52 carotid stent-
assisted angioplasty procedures to treat recurrent carotid
stenosis
Stent type No. used Size (mm)
Self-expanding
Wallstent 27 8  20 to 10  42
Precise* 12 9  30 to 10  40
SMART 6 10  30 to 10  40
Acculink† 3 10  30
Balloon-expandable 4 5  16 to 7  31
*Angioguard filter used during two procedures.
†AccuNet distal protection device used during stent deployment procedure.
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for high lesions amenable to placement above the mandi-
ble, where stent protection was achieved. Completion an-
giography with extracranial and intracranial imaging was
performed in all patients in the CAS group, and more
recently color duplex scanning has been used to monitor
adequacy of stent patency and deployment. Abciximab
(ReoPro; Eli Lilly, Indianapolis, Ind), an antagonist of
glycoprotein IIb/IIIa platelet receptors, was used selec-
tively (3 patients) to treat suspected intrastent thrombus
formation or in patients believed to be at increased risk for
CAS-related thromboemboli.
Patients in the repeat CEA group underwent open
surgical repair performed by one of three board-certified
vascular surgeons (D.F.B., M.R.B., B.L.J.) using general
anesthesia, and either routine shunting or electroencepha-
lographic monitoring during carotid occlusion. All patients
received aspirin (325 mg/d) alone or in addition to clopi-
dogrel (75 mg/d) before the procedure. Repair technique
consisted of vein (n  21) or prosthetic (n  2) patch
angioplasty (23 of 27 procedures [85%]), with endarterec-
tomy of atherosclerotic plaques (n  17) when present.
Carotid resection with autogenous vein bypass grafting was
performed in 3 patients, and 1 patient underwent primary
closure of the ICA after repeat CEA. Completion intraop-
erative duplex scanning was performed in all patients in the
repeat CEA group, and no intraoperative revisions were
required.
After intervention, patients in the CAS group were
given clopidogrel bisulfate (Plavix; 75 mg/d orally) for 30
days, and aspirin therapy has been continued indefinitely in
all patients.
Duplex ultrasound scanning surveillance. After in-
tervention for RCS, patients underwent serial color duplex
ultrasound scanning in a laboratory accredited by the Inter-
societal Commission for Accreditation of Vascular Labora-
tories, beginning at 1 month after the procedure, then
every 6 months. Duplex ultrasound scanning criteria for
recurrent stenosis with greater than 50% diameter reduc-
tion involving the repeat CEA site or stented extracranial
carotid artery segment were peak systolic velocity greater
than 125 cm/s and internal carotid artery–common ca-
rotid artery ratio greater than 2. Duplex scanning criteria
for greater than 75% stenosis were peak systolic velocity
greater than 300 cm/s and end-diastolic velocity greater
than 125 cm/s at the site of maximum stenosis, in conjunc-
tion with internal carotid artery–common carotid artery
ratio greater than 4 and high-grade lumen reduction with
poststenotic turbulence at color Doppler scanning. If end-
diastolic velocity was greater than 145 cm/s, recurrent
stenosis was classified as greater than 80% diameter reduc-
tion. Criteria for an occluded angioplasty site or surgical
repair were a clearly visualized vessel without color Doppler
flow scanning and velocity spectra of antegrade flow. Du-
plex scanning surveillance was accomplished in all patients
at 1 month, and thereafter in all surviving patients in the
repeat CEA group and 85% of patients in the CAS group.
All patients in the CAS group underwent duplex surveil-
lance scanning at least twice.
Statistical analysis. Analysis of categorical variables
between the two treatment groups was performed with 2
analysis, and continuous variables were compared with
either a two-sided t test or the Wilcoxon rank-sum test, as
appropriate. The Kaplan-Meier method was used to esti-
mate patient survival, and intervention-free and stenosis-
free patency after CAS or repeat CEA. Life-table patency
rates were compared with the log-rank test. P  .05 was
considered significant.
Table II. Demographics, associated medical conditions, and presenting symptoms in 77 patients treated for 79
recurrent carotid stenoses
CAS (n  50)
Repeat CEA
(n  27)
Pn % n %
Age (y)
Mean 70.2  8 66.5  11 .001
Range 62–84 38–79
Men 35 70 19 70 NS
Medical comorbid conditions
Hypertension 44 88 24 88 NS
Tobacco abuse 33 66 19 70 NS
Hyperlipidemia 35 70 16 59 NS
Peripheral artery disease 24 48 12 44 NS
Coronary artery disease 31 62 13 48 NS
Diabetes mellitus 8 16 8 30 .11
Presenting symptoms 52 arteries 27 arteries
Asymptomatic 21 40 10 37 NS
Symptomatic 31 60 17 63 NS
TIA or amaurosis fugax 19 37 4 15 .02
Stroke 7 13 10 37 .02
Both 5 10 3 11
CAS, Carotid stent-assisted angioplasty; CEA, carotid endarterectomy; TIA, transient ischemic attack; NS, not significant.
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RESULTS
Patient demographic data. Patients selected for CAS
were older than patients who underwent repeat CEA to
treat RCS, but the incidence of atherosclerotic risk factors
and other medical comorbid conditions were similar in the
two treatment groups (Table II). Most patients treated for
RCS had symptoms (CAS, 60%; repeat CEA, 63%), and
stroke was more common in the repeat CEA group. All
asymptomatic RCS lesions demonstrated greater than 80%
diameter reduction at both duplex scanning (end-diastolic
velocity 145 cm/s) and angiography.
The frequency of early (3 years) RCS, that is, my-
ointimal lesions, treated with CAS was greater (P .03, 2
test) than in the repeat CEA group, with mean time from
primary CEA to intervention of 50 8 months for patients
with CAS and 83  15 months patients with repeat CEA
(Table III). Overall, most RCS lesions selected for inter-
vention were symptomatic (59%; 49 of 77) and treated less
than 3 years (54%; 43 of 79) after primary CEA. Nine
patients in the CAS group were enrolled in ongoing clinical
trials studying the safety and efficacy of carotid stenting
with (Carotid Revascularization and Endarterectomy vs
Stent Trial [CREST] Lead-In, 3; Acculink for Revascular-
ization of Carotids in High-Risk Patients [ARCHER], 5)
and without (Stenting and Angioplasty with Protection in
Patients at High Risk for Endarterectomy [SAPPHIRE], 1)
cerebral protection device usage.
Periprocedural (30-day) outcome. Mortality, neu-
rologic morbidity, and overall morbidity from treating RCS
with CAS or repeat CEA were similar (Table IV). In the
repeat CEA group no patient died or sustained a myocar-
dial infarction within 30 days. One patient had a minor
ipsilateral stroke, with a cortical infarct demonstrated at
magnetic resonance imaging (MRI) after repeat CEA. This
complication was thought to be caused by an allergic
reaction to dextran-40, manifested as hypotension during
the procedure. No permanent neurologic deficit was
present in this patient at discharge. No ipsilateral TIA or
contralateral stroke occurred in the repeat CEA group. In 1
patient transient hypoglossal nerve paresis developed, with
resolution of tongue deviation by 1 month; and 1 patient
required operative evacuation of a cervical hematoma.
Overall morbidity after 27 repeat CEA procedures was 11%
(3 patients), and neurologic or stroke morbidity was 3% (1
patient).
CAS angioplasty was successful in all patients selected
for endovascular treatment. Three patients were deemed
unsatisfactory for CAS on the basis of previous cerebral
angiographic findings, and were treated surgically. In 1
patient an embolus to the middle cerebral artery developed
4 hours after the CAS procedure, and was treated with
intracerebral thrombolyis, with no neurologic sequelae or
brain abnormality at MRI. One patient (2%) died of ipsilat-
eral intracranial hemorrhage on the second postprocedure
day, after successful combined CAS–intracranial balloon
angioplasty to treat symptomatic RCS and middle cerebral
stenosis. This complication was thought related to the
intracranial procedure and not to stenting of the extracra-
nial carotid lesion. An additional patient in the CAS group
was seen 1 week after discharge, with ipsilateral arm and leg
weakness and slurred speech. Duplex scans and cerebral
angiograms demonstrated a patent carotid stent without
thrombus or residual stenosis, and no intracerebral abnor-
mality. This event was classified as a minor stroke, inasmuch
as all neurologic deficits resolved within 3 days. TIA oc-
curred in 2 patients on the day after CAS; resolution was
within hours, and brain MRI verified no abnormality. A
contralateral hemispheric lacunar stroke developed in 1
patient in the CAS group, believed due to hypertension.
Total neurologic morbidity (stroke or TIA) attributable to
the CAS procedure was 10% (5 patients), and all ipsilateral
neurologic symptoms developed more than 24 hours after
the CAS procedure. The 30-day combined stroke and
death rate after CAS was 5.7% (3 of 52 procedures).
Catheter sheath access complications developed in 2
patients in the CAS group: a brachial artery psuedoaneu-
rysm requiring surgical repair and retroperitoneal hema-
toma requiring no blood transfusion. No patient in the
CAS group had a periprocedural myocardial infarction.
Duplex ultrasound scanning surveillance. No pa-
tient had stent or ICA occlusion during mean follow-up of
Table III. Interval from CEA to treatment of RCS with
CAS or repeat CEA
CAS
(n  52)
Repeat CEA
(n  27) P
Early (36 mo) RCS 33 10 .03
Late (36 mo) RCS 19 17
Mean time to intervention (mo) 50  8 83  15 .05
Median time to intervention (mo) 24 48
CEA, Carotid endarterectomy; RCS, recurrent carotid stenosis; CAS, ca-
rotid stent-assisted angioplasty.
Table IV. Thirty-day perioperative and neurologic
outcome after 52 CAS and 27 repeat CEA for recurrent
carotid stenosis
CAS
Repeat
CEA
Pn % n %
Death 1 2 0 NS
Bleeding 2 4 1 4 NS
Myocardial infarction 0 0 NS
All ipsilateral strokes 2 4 1 4 NS
Major* 1 2 0 NS
Minor 1 2 1 4 NS
Contralateral stroke 1 2 0 NS
Ipsilateral TIA 2 6 0 NS
Intracranial embolus 1 2 0 NS
Cranial nerve injury
Transient 1
Permanent 0
CAS, Carotid stent-assisted angioplasty; CEA, carotid endarterectomy;
TIA, transient ischemic attack; NS, not significant.
*Patient died of intracerebral hemorrhage.
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34 months. Duplex scan–detected stenosis-free (50%
diameter reduction) patency for CAS (66%) was similar to
that for repeat CEA procedures (74%) at 24 months (P 
.1, log-rank test; Fig 1).
After repeat CEA, greater than 50% asymptomatic re-
current stenosis developed at five repair sites (18%). In 2
patients the lesions progressed to greater than 75% diame-
ter reduction at 10 months and 3 years, respectively, after
repeat CEA, and these patients underwent successful, un-
complicated CAS. In the remaining 3 patients with 50% to
74% diameter reduction, repeat CEA site stenosis devel-
oped at 8, 18, and 24 months, respectively; these lesions
have not progressed in severity, and all have remained
asymptomatic.
After CAS, eight stent-angioplasty sites (16%) demon-
strated intrastent (n 4) or adjacent carotid artery (n 4)
greater than 50% diameter reduction stenosis at duplex
scanning surveillance. In 1 patient in the CAS group a
motor TIA occurred at 9 months, and duplex ultrasound
scans and cerebral angiograms demonstrated 60% diameter
reduction recurrent stenosis proximal to the ICA stent (Fig
2). A second stent was placed proximal across the origin of
the ICA, and the patient has remained asymptomatic there-
after. In 3 patients the lesions progressed without neuro-
logic symptoms to greater than 80% diameter reduction
stenosis, and repeat interventions were performed at 5, 11,
and 12 months, respectively, after CAS. High-grade
(80%) stenosis was confirmed at angiography, and repeat
intervention with balloon dilation (n1) or stent-angioplasty
(n 3) was successful and without neurologic complication.
In 4 patients with duplex scanning–detected stent stenosis
of 50% to 74%, the lesions have remained asymptomatic,
with regression to less than 50% stenosis in 1 patient.
Late clinical outcome. Freedom from repeat inter-
vention and stroke rates after CAS and repeat CEA were
identical (89%) by life-table analysis at 36 months (Fig 3).
No patient had ipsilateral stroke attributable to the repeat
CEA or CAS site during mean follow-up of 39 and 26
months, respectively. The incidence of recurrent ipsilateral
neurologic symptoms due to recurrent stenosis or treat-
ment of asymptomatic greater than 80% recurrent stenosis
was similar in the CAS group (4 of 51 procedures [8%]) and
repeat CEA group (2 of 27 procedures [7%]). Patient
survival at 36 months after intervention for RCS was equiv-
alent in the repeat CEA (92%) and CAS (92%) groups (Fig
4). In the repeat CEA group 2 patients died of coronary
artery occlusive disease, and in the CAS group 1 patient
died of coronary artery occlusive disease, 3 patients died of
cancer, and 1 patient died of undetermined cause.
DISCUSSION
Management of RCS with CAS was associated with
neurologic and anatomic outcome similar to that after open
surgical repair with patch angioplasty or carotid artery
resection. Accounting for differences in patient factors,
including frequency of myointimal lesions, the procedure-
related stroke and death rate was similar for CAS (6%) and
repeat CEA (3%), as was overall 30-day morbidity, at 12%
and 11%, respectively. These mortality and neurologic mor-
bidity rates were similar to our results with primary CEA
(1.7%),10 as well as recent reports of CAS (2.4%-
4.3%)5,7,9,11 and repeat CEA (0%-5%)1,3,4,6,12-15 outcome
for RCS. We have not limited the use of CAS to treatment
of early myointimal lesions. In fact, one third of lesions
treated with CAS developed more than 3 years after the
primary CEA procedure and had duplex scanning and
angiographic features of recurrent carotid bifurcation ath-
Fig 1. Stenosis-free (50% diameter reduction) primary patency
after carotid stent-assisted angioplasty (CAS; n  51) or repeat
carotid endarterectomy (Redo-CEA; n  27).
Fig 2. Left, Angiogram demonstrates 60% recurrent stenosis
proximal to an internal carotid artery stent that developed 9
months after carotid angioplasty and was associated with recurrent
amaurosis fugax. Right, Treatment with a second stent corrected
the recurrent stenosis.
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erosclerosis. In addition, approximately half of the CAS
group could be considered at high risk because of contralat-
eral ICA occlusion (n  14) or judged not to be surgical
candidates (n  17). Of note, a distal protection or “an-
tiembolic” device was used in 6 patients in the CAS group
enrolled in the National Institutes of Health–sponsored
CREST (n  3) or Guidant-sponsored ARCHER (n  5)
clinical trials. Despite these differences in patients treated,
equivalent results were obtained with CAS and repeat CEA.
We believe surgical repair should continue to be the pre-
ferred option, especially in patients at good risk with exten-
sive RCS involving both the common and internal carotid
artery segments, and for RCS associated with mural throm-
bus, aneurysm dilation, or ICA tortousity. Repeat carotid
surgery has a proved track record, and provides long-term
freedom from stroke and recurrent stenosis.14,15
In our practice, selection of patients for CAS was based
primarily on the presence of aortic arch and carotid anat-
omy appropriate for CAS. However, some patients in the
CAS group were referred from other surgeons specifically
for endovascular management, because they would not
consent to repeat CEA, and 9 patients were enrolled in
clinical trails (CREST, ARCHER, SAPPHIRE) as “high-
risk” patients on the basis of an RCS lesion. A significant
number of patients, 17 of 50 (34%) in the CAS group were
judged not to be suitable surgical candidates, most com-
monly because of a surgically inaccessible distal ICA lesion,
advanced cardiorespiratory disease, or RCS in an irradiated
or scarred neck. Thus, having the capability to perform
CAS increased the number of patients who could undergo
intervention for RCS. The ability to treat the spectrum of
patients with RCS is important for a tertiary vascular sur-
gery practice.
Most patients with RCS have anatomy appropriate for
endovascular management. We averted use of CAS on
lesions with angiographic features of irregular, mural
thrombus or when significant ICA tortousity precluded
“safe” stent deployment. Despite careful patient selection,
three CAS procedures were complicated by development of
stent thrombus or distal embolization requiring cerebro-
vascular rescue with catheter-directed thrombolysis or ad-
ministration of abciximab. Having the skills to deal with
stenting complications is critical if procedure-related mor-
bidity is to be minimized and be comparable to surgical
repair.
Our experience in evaluating and treating patients with
RCS indicates the natural history of this lesion, including
early (1 year) myointimal stenosis, was associated with
low incidence of disabling stroke or progression to ICA
occlusion. After treatment with CAS or repeat CEA, no
stent angioplasty or carotid repair site became occluded,
and no ipsilateral stroke occurred. Only 1 patient had
recurrent symptoms (amaurosis fugax after CAS), due to
50% to 74% diameter reduction recurrent stenosis proximal
to the stent. We found duplex scanning surveillance to be
worthwhile, inasmuch as greater than 50% recurrent steno-
sis developed in 16% of stented segments and 18% of
carotid repairs. Progression to high-grade greater than 75%
diameter reduction stenosis was observed in half of our
patients, all without development of neurologic symptoms,
and led to endovascular repeat intervention in 6 patients, 2
after repeat CEA and 4 after CAS. The durability of CAS in
treating RCS, as measured by duplex scanning monitored
stenosis-free patency, was comparable to repeat CEA, 66%
versus 74%, respectively, at 2 years. While duplex scanning–
detected recurrent stenosis rate of 40% to 50% at 2 to 3
years after CAS has been reported, it appears the recurrent
stenosis rate leading to endovascular or surgical interven-
tion is in the range of 10% to 15%.4,5,16 These results
support routine use of duplex scanning surveillance after
both CAS and repeat CEA procedures. We recommend
Fig 3. Freedom from repeat intervention for recurrent stenosis
after treatment for recurrent carotid stenosis with carotid stent-
assisted angioplasty (CAS; n  51) or repeat carotid endarterec-
tomy (Redo-CEA; n  27).
Fig 4. Survival of 77 patients after treatment of recurrent carotid
stenosis with carotid stent-assisted angioplasty (CAS; n50) or
surgical repair (redo-CEA; n  27).
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angiography and consideration of endovascular repair with
balloon dilation or stent-assisted angioplasty in patients
when a duplex scan demonstrates greater than 80% diame-
ter reduction stenosis (end-diastolic volume 145 cm/s)
at the RCS repair site.
The effectiveness of CAS in treating extracranial carotid
occlusive disease has been confirmed at multiple institu-
tions, and has led to prospective multicenter clinical trials to
verify equipoise of CAS with CEA. Because of the inherent
increased risk for embolic complications associated with
CAS, it is appropriate that efficacy of protection devices also
be studied.17 Antiembolic devices provide cerebral protec-
tion only while deployed in the distal ICA. Risk for lesion or
device embolization during lesion traversal or device re-
moval and immediately after CAS will still be present.
Careful patient preparation before CAS, appropriate cath-
eter techniques in performing cerebrovascular interven-
tions, and verification of technically adequate stent deploy-
ment may be equally important in reducing neurologic
complications. The principal benefit of using distal protec-
tion devices in treating RCS may be the increased number
of patients who would be candidates for treatment of
lesions thought to be at “higher” risk for embolization. At
present our experience demonstrates that carotid angio-
plasty provides equivalent protection against stroke and
ICA occlusion compared with open surgical procedures in
treatment of both early and late RCS. Ideally, in the future
carotid angioplasty will be compared with repeat carotid
surgery in a controlled, randomized, multicenter clinical
trial.
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